Drug intelligence / Profile preview

GSK2800528

Development stage: Phase 1
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GSK2800528 is a human monoclonal antibody developed by GSK that acts as a tumor necrosis factor alpha (TNF-α) inhibitor. It is designed to target and inhibit TNF-α, a cytokine involved in systemic inflammation and immune system diseases. The drug is primarily being investigated for the treatment of immune-inflammatory conditions such as psoriasis and other skin and musculoskeletal diseases. Its mechanism of action involves binding to TNF-α to neutralize its pro-inflammatory effects, thereby modulating the immune response.

Other names: GSK-2800528GSK2800528GSK 2800528

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on GSK2800528.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2800528.

Explore the full profile